-
公开(公告)号：US20150139984A1
公开(公告)日：2015-05-21
申请号：US14492250
申请日：2014-09-22
Applicant: JANSSEN BIOTECH, INC.
Inventor： Randall Brezski , Robert Jordan , William Strohl
CPC classification number: C07K16/30 , C07K16/00 , C07K16/22 , C07K16/2863 , C07K16/2887 , C07K16/2896 , C07K16/40 , C07K2317/52 , C07K2317/524 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with FcγR receptors except with FcγRI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.
Abstract translation: 本发明涉及修饰的含Fc分子，包括特征在于对宿主和病原体衍生的蛋白酶的抗性增加，与FcγRI之外的FcγR受体相互作用的能力和由巨噬细胞诱导IL-10分泌的方法， 使用和使他们。
-
2.发明授权公开(公告)号：US11096998B2
公开(公告)日：2021-08-24
申请号：US16323121
申请日：2017-09-11
Applicant: Janssen Biotech, Inc.
Inventor： Chen Ni Chin , John Lee , Timothy McCabe , Jill Mooney , Michael Naso , William Strohl
IPC: C07K16/00 , C07K16/46 , C07K16/28 , A61K39/00 , C12N15/82 , A61P35/00 , C07K14/525 , C07K14/705 , C07K14/75 , C07K14/78
Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
-
3.发明申请公开(公告)号：US20190330361A1
公开(公告)日：2019-10-31
申请号：US16323121
申请日：2017-09-11
Applicant: Janssen Biotech, Inc.
Inventor： Chen Ni Chin , John Lee , Timothy McCabe , Jill Mooney , Michael Naso , William Strohl
Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
-
公开(公告)号：US20180319893A1
公开(公告)日：2018-11-08
申请号：US16037304
申请日：2018-07-17
Applicant: Janssen Biotech, Inc.
Inventor： McCarthy Stephen , Bernard Scallon , William Strohl , Susan Tam , Omid Vafa
CPC classification number: C07K16/32 , A61K2039/505 , C07K16/00 , C07K16/2887 , C07K2317/52 , C07K2317/524 , C07K2317/54 , C07K2317/70 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
-
公开(公告)号：US20170204193A1
公开(公告)日：2017-07-20
申请号：US15463716
申请日：2017-03-20
Applicant: Janssen Biotech, Inc.
Inventor： William Strohl , Omid Vafa
CPC classification number: C07K16/32 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/2887 , C07K2317/52 , C07K2317/524 , C07K2317/54 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
-
Patent Agency Ranking
公开(公告)号：US09611328B2
公开(公告)日：2017-04-04
申请号：US14492250
申请日：2014-09-22
Applicant: JANSSEN BIOTECH, INC.
Inventor： Randall Brezski , Robert Jordan , William Strohl
CPC classification number: C07K16/30 , C07K16/00 , C07K16/22 , C07K16/2863 , C07K16/2887 , C07K16/2896 , C07K16/40 , C07K2317/52 , C07K2317/524 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to modified Fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with FcγR receptors except with FcγRI, and lack of induction of IL-10 secretion by macrophages, and methods of using and making them.
-
7.发明申请公开(公告)号：US20150210756A1
公开(公告)日：2015-07-30
申请号：US14565069
申请日：2014-12-09
Applicant: New York University , Janssen Biotech, Inc.
Inventor： Victor J. Torres , Randall J. Brezski , Anthony Lynch , William Strohl , Brian Whitaker , Mark Chiu , Peter T. Buckley , Keri Dorn , Michelle Kinder
IPC: C07K16/12 , G01N33/569
CPC classification number: C07K16/1271 , C07K14/78 , C07K2317/30 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2318/00 , C07K2319/70 , G01N33/56938 , G01N2469/10
Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
Abstract translation: 本申请通常涉及结合多种细菌毒力因子的多特异性分子，用于产生这些结合分子的方法，以及这些结合分子用于治疗细菌感染的用途。 特别地，结合分子包含至少两个结合结构域，优选抗体或抗体片段和替代性支架。 第一结合结构域能够结合糖基化的葡萄球菌表面蛋白，优选含有SDR的蛋白质。 第二结合结构域能够结合葡萄球菌白血病，优选LukAB，LukD或LukE。 这些多特异性结合化合物对葡萄球菌具有杀伤活性，因此可用于治疗和/或改善葡萄球菌感染，包括耐甲氧西林金黄色葡萄球菌。
-
公开(公告)号：US20150118227A1
公开(公告)日：2015-04-30
申请号：US14597690
申请日：2015-01-15
Applicant: Janssen Biotech, Inc.
Inventor： William Strohl , Omid Vafa
CPC classification number: C07K16/32 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/2887 , C07K2317/52 , C07K2317/524 , C07K2317/54 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92
Abstract: Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
Abstract translation: 具有Fc区变化的抗体和其它含Fc的分子减少与Fcγ受体的结合并导致其活性，并可用于治疗各种疾病和病症。
-
公开(公告)号：US20210155711A1
公开(公告)日：2021-05-27
申请号：US17150269
申请日：2021-01-15
Applicant: Janssen Biotech, Inc.
Inventor： Stephen McCarthy , Bernard Scallon , William Strohl , Susan Tam , Omid Vafa
Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
-
公开(公告)号：US10894836B2
公开(公告)日：2021-01-19
申请号：US16037304
申请日：2018-07-17
Applicant: Janssen Biotech, Inc.
Inventor： McCarthy Stephen , Bernard Scallon , William Strohl , Susan Tam , Omid Vafa
Abstract: Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.023 seconds)
